Skip to main content
Fig. 5 | Lipids in Health and Disease

Fig. 5

From: Metabolic profiling reveals interleukin-17A monoclonal antibody treatment ameliorate lipids metabolism with the potentiality to reduce cardiovascular risk in psoriasis patients

Fig. 5

Scatter plots of highlighted metabolites in study cohorts 1 and 2. The metabolic changes in six ixekizumab-treated individuals from the PC group in the study cohort 2 conformed to previous observations in study cohort 1. *P < 0.05, **P < 0.01, ***P < 0.001. CON: group of healthy controls; PSO: group of psoriasis patients; IXE: group of ixekizumab-treated psoriasis patients; PC: group of psoriasis patients with coronary heart disease; CV: group of coronary heart disease patients without psoriasis

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X